Previous studies of DPPIVi and basal insulin use in patients with type 2 diabetes have shown that this combination therapy leads to improved glycaemic control compared with basal insulin alone without an increase in hypoglycaemia, and with little or no effect on body weight or insulin dose [7–13]. This evidence concerns the gene INS and type 2 diabetes mellitus.